Safety and Performance of the CG-100 in Patients Undergoing Colorectal Surgery.

NCT ID: NCT03423485

Last Updated: 2018-10-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 137 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-01
• Study Completion Date: 2019-07-31

Brief Summary

The purpose of this study is to evaluate the CG-100 device, a single use, temporary intraluminal bypass device,intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)

Detailed Description

Colospan is initiating a pivotal clinical prospective, multi-center, single-arm, open-label study designed to evaluate safety and performance profile of the CG-100 Intraluminal Bypass Device in patients undergoing colorectal surgery study.

Up to 137 patients (in total) will be enrolled in up to 12 sites in Europe, Israel and USA.

Study objectives Primary Objective: To evaluate the performance of the CG-100 Intraluminal Bypass Device, in reducing contact of fecal content with an anastomotic site in patients undergoing colorectal surgery (open, robotic, or laparoscopic) Secondary Objectives: To evaluate Performance in terms of clinical and radiological anastomotic leakage Successful positioning and maintenance of device position To assess the ease of the device's application and removal Safety: To assess the safety profile of the CG-100 Intraluminal Bypass Device.

Conditions

Colorectal Surgery

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Study arm

Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device

Group Type: EXPERIMENTAL

CG-100 Intraluminal Bypass Device

Intervention Type: DEVICE

Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.

Interventions

CG-100 Intraluminal Bypass Device

Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The patient is willing to comply with protocol-specified follow-up evaluations

2. Patient 22-75 years of age at screening

3. The patient is scheduled to undergo an elective colorectal surgery (open, laparoscopic, or robotic) which will require the creation of an anastomosis, maximally 20 cm proximal from the anal verge

4. The patient or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).

Exclusion Criteria

Preoperative

1. Pregnant or nursing female subjects. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.

2. Patient surgical treatment is acute (not elective)

3. Patient has local or systemic infection at the time of intervention (e.g., peritonitis)

4. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study

5. Patients with ASA classification > 3

6. Albumin < 30 g/liter

7. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease

8. BMI ≥ 40

9. Subject is going through another surgical procedure (other than ileostomy or adhesiolysis) during the surgery.

10. Patient is participating in another clinical trial within 30 days of screening

11. Patient has been taking regular steroid medication in the last 6 months.

12. Patient has contraindications to general anesthesia

13. Patient has preexisting sphincter problems

14. Patient has evidence of extensive local disease in the pelvis

15. Any condition which in the opinion of the investigator may jeopardize the patient's safe participation Intraoperative (prior to device deployment)

16. Anastomosis is located more than 20 cm from the anal verge

17. Internal diameter lumen of the colon is smaller than 25 mm or larger than 34 mm

18. Blood loss (> 500 cc)

19. Anastomosis was not performed for any reason other than consequences as a result of use of the study device -

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Colospan Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ilia Pinsk, MD

Role: PRINCIPAL_INVESTIGATOR

Soroka University Medical Center

Locations

Hospital Beaujon

Paris, Clichy, France

Site Status: RECRUITING

University Hospital of Hamburg

Hamburg, , Germany

Site Status: RECRUITING

Soroka Medical Center

Beersheba, , Israel

Site Status: RECRUITING

Carmel Medical Center

Haifa, , Israel

Site Status: RECRUITING

CHUV, University Hospital Vaudois

Lausanne, , Switzerland

Site Status: RECRUITING

Countries

France; Germany; Israel; Switzerland

Central Contacts

Ilia Pinsk, MD

Role: CONTACT

IliaPi@clalit.org.il

+972-8-6400561

Avi Sechef, MD

Role: CONTACT

ReshefAv@clalit.org.il

+972-8-6400561

Facility Contacts

Yves Panis, Prof.

Role: primary

yves.panis@bjn.aphp.fr

01 40 87 45 47

Daniel Perez, Dr.

Role: primary

d.perez@uke.de

0049 152 2282 7310

Ilia Pinsk, MD

Role: primary

iliapi@clalit.org.il

+972-8-6400250

Wisam Khoury, Dr.

Role: primary

WisamK@clalit.org.il

972 04 8250490

Martin Huebner, Dr.

Role: primary

Martin.Hubner@chuv.ch

079 556 8838

Other Identifiers

CLD-017

Identifier Type: -

Identifier Source: org_study_id